Clinical Trial

A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-19.
Status change: Not Yet Recruiting → Recruiting 2025-05-14
Trial Details
NCT Number NCT06474442
Lead Sponsor Shanghai BDgene Co., Ltd.
Conditions Herpes Simplex Virus Type I Stromal Keratitis
Enrollment 40 participants
Start Date 2025-04-28
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-05-18